Breast cancer cryoablation safe alternative for high-risk patients, suggests study

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-07-14 16:15 GMT | Update On 2024-07-15 05:58 GMT

Researchers have found that breast cancer cryoablation provides a safe and effective alternative to surgical excision in patients with unfavorable characteristics, and it also provides good outcomes for women who are not candidates for clinical trials. The study was published in the American Journal of Roentgenology by Karim Q. and colleagues.

Breast cancer cryoablation is a minimally invasive procedure that uses extreme cold to destroy cancer cells. The corresponding clinical trials are extremely selective in their inclusion criteria and usually involve only patients with potentially treatable diseases. This study evaluated the safety and outcomes of cryoablation in a real-world, broader patient population: those ineligible for clinical trials because of unfavorable patient or tumor characteristics.

The primary endpoint of the study was to assess the safety and efficacy of cryoablation of breast cancer without surgical excision in patients ineligible for clinical trials. This was a retrospective study of women who underwent cryoablation of biopsy-proven unifocal primary breast cancer with locally curative intent. These procedures were carried out from 1 January 2000 to 26 August 2021 in seven institutions. Adverse events were recorded, with the cryoablation procedures labeled as technically successful if they met parameters for the treatment with no reveal of residual disease at first imaging follow-up. Follow-up biopsies and ipsilateral breast tumor recurrences (IBTR) also were documented.

The final study sample included 112 patients with a median age of 71 years. The findings are as follows:

• Only 6.3% of the patients developed minor AEs; no moderate or major AEs were reported.

• Technical success was achieved in 98.2% (110/112) of the cryoablation procedures.

• Over a median follow-up of 2.0 years, 20.0% of patients had undergone biopsies for suspicious imaging findings. Of these, 40.9% (9/22) were benign, and 54.5% (12/22) were IBTR.

• 10.9% (12/110) of patients experienced IBTR, with 7 cases of true recurrence and 5 of new primary disease. Among these, 25.0% (3/12) had received earlier adjuvant or neoadjuvant therapy.

When accounting for death as a competing risk, the cumulative incidence of IBTR was:

• 5.3% at 1 year

• 12.2% at 2 years

• 18.2% at 3 years

These results indicate that breast cancer cryoablation can be safely applied to a broader patient population than defined by current clinical trial inclusion criteria. The high technical success rate and manageable AE profile support cryoablation as a viable alternative to surgery, particularly for patients who are poor surgical candidates due to age, comorbidities, or other factors.

This study demonstrates that breast cancer cryoablation could be safely and effectively extended to even more patients who previously could not participate in clinical trials. This is very important for patients who are poor surgical candidates, providing them with a minimally invasive option with good outcomes. Breast cancer cryoablation is a safe surgical alternative with favorable outcomes for select patients with unfavorable characteristics.

Reference:

Oueidat, K., Baird, G. L., Barclay-White, B., Kozlowski, K., Plaza, M. J., Aoun, H., Tomkovich, K., Littrup, P. J., Pigg, N., & Ward, R. C. (2024). Cryoablation of primary breast cancer in patients ineligible for clinical trials: A multiinstitutional study. AJR. American Journal of Roentgenology. https://doi.org/10.2214/ajr.24.31392

Article Source : American Journal of Roentgenology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr Riya Dave

Dr Riya Dave has completed dentistry from Gujarat University in 2022. She is a dentist and accomplished medical and scientific writer known for her commitment to bridging the gap between clinical expertise and accessible healthcare information. She has been actively involved in writing blogs related to health and wellness.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Breast cancer cryoablation safe alternative for high-risk patients, suggests study

Similar News

FDA Grants Accelerated Approval to Zongertinib for HER2-Mutated NSCLC

Tumor diagnostics: AI model detects more than 170 types of cancer

DMFT Score associated with increased risk of Buccal Mucosa Cancer: Study

AI software on targeted USG effective in diagnosing mass and non-mass breast lesions: Study

Study reports final clinical trial data for advanced kidney cancer treatment

Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Rectal Cancer - Dr. Poulami Basu

Thyroid Dysfunction Common After Radiotherapy in Head and Neck Cancer Patients, Study Warns

Not all low-grade prostate cancers are low risk: JAMA